tbuckley/cabot-search huggingface dataset:
Feasibility and Efficacy of a Planned Second Transplant (“auto” or “mini-allo”) Intensification in Patients with Multiple Myeloma (MM) Not Achieving Complete Remission (CR) or Near-CR with a First Autologous Transplant. Results from a Spanish PETHEMA/GEM Study.
Authors: L. Rosiñol, J. J. Lahuerta, A. Sureda, J. de la Rubia, J. García-Laraña, M. Hernández-García, B. Hernández-Ruíz, J. A. Pérez-Simón, J. L. Bello, D. Carrera, M. J. Peñarrubia, E. Abella, A. León, C. Poderós, J. C. García-Ruíz, J. Besalduch, R. Martínez-Martínez, I. Pérez-Fernández, P. Ribas, F. Escalante, J. San Miguel, J. Bladé.
Journal: Blood (2005)
The effect of patient age at intervention on risk of implant revision after total replacement of the hip or knee: a population-based cohort study
Authors: Lee E Bayliss, David Culliford, A Paul Monk, Sion Glyn-Jones, Daniel Prieto-Alhambra, Andrew Judge, Cyrus Cooper, Andrew J Carr, Nigel K Arden, David J Beard, Andrew J Price
Journal: The Lancet (2017)

BackgroundTotal joint replacements for end-stage osteoarthritis of the hip and knee are cost-effective and demonstrate significant clinical improvement. However, robust population based lifetime-risk data for implant revision are not available to aid patient decision making, which is a particular problem in young patient groups deciding on best-timing for surgery.MethodsWe did implant survival analysis on all patients within the Clinical Practice Research Datalink who had undergone total hip replacement or total knee replacement. These data were adjusted for all-cause mortality with data from the Office for National Statistics and used to generate lifetime risks of revision surgery based on increasing age at the time of primary surgery.FindingsWe identified 63 158 patients who had undergone total hip replacement and 54 276 who had total knee replacement between Jan 1, 1991, and Aug 10, 2011, and followed up these patients to a maximum of 20 years. For total hip replacement, 10-year implant survival rate was 95·6% (95% CI 95·3–95·9) and 20-year rate was 85·0% (83·2–86·6). For total knee replacement, 10-year implant survival rate was 96·1% (95·8–96·4), and 20-year implant survival rate was 89·7% (87·5–91·5). The lifetime risk of requiring revision surgery in patients who had total hip replacement or total knee replacement over the age of 70 years was about 5% with no difference between sexes. For those who had surgery younger than 70 years, however, the lifetime risk of revision increased for younger patients, up to 35% (95% CI 30·9–39·1) for men in their early 50s, with large differences seen between male and female patients (15% lower for women in same age group). The median time to revision for patients who had surgery younger than age 60 was 4·4 years.InterpretationOur study used novel methodology to investigate and offer new insight into the importance of young age and risk of revision after total hip or knee replacement. Our evidence challenges the increasing trend for more total hip replacements and total knee replacements to be done in the younger patient group, and these data should be offered to patients as part of the shared decision making process.FundingOxford Musculoskeletal Biomedical Research Unit, National Institute for Health Research.
NTOX-13. THROMBOPOIETIN RECEPTOR AGONISTS ARE EFFECTIVE IN TREATING CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA, IN PATIENTS WITH GLIOMAS UNDERGOING MYELOTOXIC TREATMENT
Authors: Chris Dardis, Kelly Milton
Journal: Neuro-Oncology (2016)

Thrombocytopenia is the principal dose-limiting toxicity in patients with glial tumors undergoing chemotherapy. The problem occurs in up to 20% of such patients treated. Our HYPOTHESIS was that a thrombopoetin analogue would be useful in 1) reversing thrombocytopenia and 2) in allowing the continuation of chemotherapy as planned. DESIGN: Retrospective, unblinded case series. We reviewed all patients prescribed a thrombopoetin agonist at our clinic over a period of 18 months. Treatment was initiated if felt to be in the patient’s best interests. PARTICIPANTS: Consecutive patients undergoing chemotherapy for glial tumors (glioblastoma, astrocytoma, oligodendroglioma) who were prescribed a thrombopoetin agonist. INTERVENTION: Use of eltrombopag 50 to 200 mg po daily or romiplostim 1 to 10 microg/kg/week subcut. Treatments were continued as long as the patient remained on chemotherapy. RESULTS: Of 27 patients treated (21 with glioblastome), all but one were able to continue chemotherapy. Mean platelet nadir was 65 x10^9/L and occurred at median of 4.4 after starting chemotherapy. Median additional time on chemotherapy was 18.2 months. (95% CI 16.1 - NA). The exception was a patient previously treated for AML in childhood. One patient developed a mild itch, requiring eltrombopag to be given every 3. There was one sudden death, which appears unrelated. Mean total additional chemotherapy given was: temozolomide 5570 mg/m2, bevacizumab 120 mg/kg, lomustine 110 mg/m2. CONCLUSIONS: This intervention appears to be safe and effective for this problem. With such treatment, a longer duration of chemotherapy appears possible than would otherwise be the case. A larger series will be needed to determine whether this translates into improved clinical outcomes. Being a common problem throughout oncology, we believe that these treatments are deserving of wider investigation, for other myelotoxic chemotherapies.
Patients with Immunoglobulin Light Chain Amyloidosis (AL) Undergoing High Dose Chemotherapy with Autologous Stem Cell Transplantation (ASCT) have Superior Outcomes As Compared to Patients with Multiple Myeloma (MM)
Authors: Kirupananthan Seenithamby, Angela Dispenzieri, Martha Q Lacy, Shaji K. Kumar, Francis K Buadi, Suzanne R Hayman, David Dingli, Mark R Litzow, Dennis A. Gastineau, David J. Inwards, Ivana N. Micallef, Stephen M. Ansell, Patrick B. Johnston, Luis F. Porrata, Mrinal M. Patnaik, William J Hogan, Morie Abraham A Gertz
Journal: Blood (2012)
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Authors: Deborah A. Knight, Shin Foong Ngiow, Ming Li, Tiffany Parmenter, Stephen Mok, Ashley Cass, Nicole M. Haynes, Kathryn Kinross, Hideo Yagita, Richard C. Koya, Thomas G. Graeber, Antoni Ribas, Grant A. McArthur, Mark J. Smyth
Journal: Journal of Clinical Investigation (2013)
Umbilical Cord Blood Is the Most Significant Risk Factor for the Development of Bloodstream Infection after Allogeneic Hematopoietic Cell Transplantation
Authors: Shinsuke Takagi, Hideki Araoka, Naoyuki Uchida, Masahiro Abe, Mitsuhiro Yuasa, Kosei Kageyama, Daisuke Kaji, Aya Nishida, Muneyoshi Kimura, Kazuya Ishiwata, Hisashi Yamamoto, Go Yamamoto, Yuki Asano-Mori, Koji Izutsu, Atsushi Wake, Akiko Yoneyama, Shuichi Taniguchi
Journal: Blood (2015)
Chemotherapy-induced interstitial pneumonia in patients with lymphoma
Authors: W.P. Liu, X.P. Wang, W. Zheng, M.F. Tu, Y. Xie, N.J. Lin, L. Ping, Z.T. Ying, C. Zhang, L.J. Deng, Y.Q. Song, J. Zhu
Journal: Annals of Oncology (2016)
Dasatinib (SprycelTM) Inhibits Osteoclast Activity in Vitro and in Vivo Via a C-Fms-Dependent and C-Src-Independent Mechanism
Authors: Kate Vandyke, Andrea Dewar, Peter Diamond, Stephen Fitter, Amanda N Farrugia, Luen Bik To, Timothy P. Hughes, Andrew Christopher William Zannettino
Journal: Blood (2008)
Functional Characterization of T- and NK-Cells in Chronic Myeloid Leukemia Patients Treated with Interferon-α Monotherapy.
Authors: Mette Matilda Ilander, Anna Kreutzman, Peter Rohon, Teresa Melo, Edgar Faber, Kimmo Porkka, Jukka Vakkila, Satu Mustjoki
Journal: Blood (2012)
Relaxing the Protected Environment Has Not Adversely Impacted Early Outcome of Older Patients (≥ 50 years) with AML and HR- MDS Receiving Induction Therapy
Authors: Gloria Mattiuzzi, Edythe Greenberg, Sherry Pierce, Jorge Cortes, Emil Freireich, Susan O’Brien, Hagop Kantarjian
Journal: Blood (2008)
GPs are unsure about prescribing tamoxifen to prevent breast cancer
Authors: Jacqui Wise
Journal: BMJ (2017)

GPs are largely unaware that tamoxifen can be prescribed for primary prevention of breast cancer, and a significant minority may be unwilling to prescribe it for eligible patients, a study published in the British Journal of General Practice has found.1

In 2013 the National Institute for Health and Care Excellence (NICE) recommended that tamoxifen or raloxifene should be offered to women at high risk of breast cancer due to family history.2 These selective oestrogen receptor modulators have been shown to …
RARE-13. DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR OF GANGLIOGLIOMA TYPE WITH V600E MUTATION IN THE BRAF GENE
Authors: María Emilia Paday
Journal: Neuro-Oncology (2016)

A 2-year-old patient with hydrocephalus, VP shunt and a history of diffuse brain and spinal cord leptomeningeal lesions without definitive diagnosis after biopsy was referred to our institution. Contrast enhanced magnetic resonance imaging (MRI) of the brain and spinal cord was acquired. Brain MRI showed multiple enhancing supra and infratentorial leptomeningeal nodules with involvement of cranial nerves and basal cisterns. Spinal cord MRI showed pseudonodular meningeal thickening that enhanced after contrast administration and generated mass effect with compression of the spinal cord. The results of the cultures and immunological studies were negative. Paravermian excision of a nodular lesion was performed. Histological section stained with hematoxilin and eosin showed proliferation of neoplastic cells with vesicular nuclei and ganglionic cytoplasm, intermixed with cells with elongated nuclei and cytoplasm processes Immunostaining were positive for synaptofisin, neurofilament and GFAP. Histopathologic diagnosis of a diffuse leptomeningeal glioneuronal tumor of ganglioglioma type was established, with V600E mutation in the BRAF gene Chemotherapy was indicated with weekly vinblastine. Two months later, the patient had progressive disease with left facial nerve and right abducens nerve paralysis. It was decided to change treatment to Vemurafenib with initially good clinical response.
Improving the Evidence Base for Delivery of High-Quality Cancer Care
Authors: Zaina P. Qureshi, Patricia A. Ganz, Charles L. Bennett
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Metronomic oral cyclosphosphamide as 3rd line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma
Authors: V.H. Lee, D.W. Kwong, Y.-C. Lai, Y. Li, K.-O. Lam, P.Y.P. Ho, W.-L. Chan, L.-S. Wong, D.K. Leung, S.-Y. Chan, F.-T. Chan, K.-S. Lau, R.P. Tse, T.-W. Leung, A. Lee
Journal: Annals of Oncology (2016)
Results of Neoteam: A randomized multicenter phase II study of liposomal doxorubicin hydrochloride + trastuzumab vs conventional doxorubicin both in combination with cyclophosphamide and followed by docetaxel + trastuzumab as neoadjuvant treatment of HER2-positive primary breast cancer
Authors: S. Pernas Simon, M. Rezai, M. Hauschild, J.P. Machiels, S. Paepke, A. Llombart Cussac
Journal: Annals of Oncology (2016)
Chronic Lymphocytic Leukemia in Young (≤ 55 years) Patients: A Comprehensive Analysis of Prognostic Factors and Outcomes.
Authors: Sameer A. Parikh, Kari G. Rabe, Neil E. Kay, Timothy G. Call, Wei Ding, Susan Schwager, Diane F. Jelinek, Susan L Slager, Tait D. Shanafelt
Journal: Blood (2012)
Multiplex Assay for Profiling Plasma Protein Biomarkers for Improved Diagnosis and Prognosis of Heparin Induced Thrombocytopenia (HIT).
Authors: Resmi Ravindran, Imran Khan, Robert C. Gosselin, Ted Wun, Krish Krishnan, Paul Luciw, Kim A. Janatpour
Journal: Blood (2006)
Screening of malignant melanoma (MM) by miRNA: preliminary data on incidence after initial clinical evaluation
Authors: M. Occelli, C. Cauhi, G. Sciancalepore, C. Lo Nigro, M. Rovera, C. Varamo, D. Vivenza, Z. Seia, S. Palazzini, F. Errico, D. Basso, L. Quaranta, G. Forte, F. Lavagna, S. Violante, P. Bosio, L. Lattanzio, M.C. Merlano
Journal: Annals of Oncology (2016)
Over the years change in prostate cancer management through the multidisciplinary team at a community hospital
Authors: A. Coinu, F. Petrelli, M. Cabiddu, K. Borgonovo, M. Ghilardi, I. Vavassori, R. Milesi, D. Taglialatela, Y. Hussein, F. Ceresoli, A. Del Rosso, R. Lisanti, A. De Stefani, V. Riboldi, E. Vitali, L. Bruschieri, E. Sarti, S. Barni
Journal: Annals of Oncology (2016)
A phase Ib dose-finding study of alpelisib (ALP; BYL719) and paclitaxel (PTX) in advanced solid tumors (aST)
Authors: J. Rodón, G. Curigliano, J.-P. Delord, W. Harb, A. Azaro, V. Donnet, Y. Han, L. Blumenstein, C. Wilke, J.T. Beck
Journal: Annals of Oncology (2016)
MPTH-46. A PILOT STUDY IDENTIFYING CIRCULATING CELL-FREE TUMOR DNA ALTERATIONS IN PATIENTS WITH GLIOBLASTOMA
Authors: Adriana Olar, Ravesanker Ezhilarasan, Meenakshi Mehrotra, Jawad Manekia, Rajesh Singh, Erik Sulman, Rajyalakshmi Luthra
Journal: Neuro-Oncology (2016)

Liquid biopsy represents a minimally-invasive blood test that is able to detect circulating tumor cells and circulating cell-free DNA (cfDNA), as well as larger fragments of tumor shed in the bloodstream from primary and metastatic solid tumors. It is an important modality to measure residual disease in patients with solid tumors, monitor disease progression and response to treatment. In primary brain tumors, the central nervous system (CNS) poses a challenge to tumor cell/cfDNA shedding due to the presence of the blood brain barrier. The primary goal of this work was to determine if patients with GBM have detectable circulating free tumor DNA (cft) in the bloodstream using deep, next generation sequencing (NGS). Sixteen resected glioblastoma specimens and matched plasma samples were sequenced using the commercially available 50-gene panel library Ion AmpliSeq™Cancer Hotspot Panel v2 (ThermoFisher) on an Ion Proton sequencer. All plasma samples were collected post-surgery of which 2 were collected post-adjuvant treatment. Time from tumor resection to plasma collection ranged from 13 to 284 (median=28.5) days. Thirty three genetic alterations were identified in tissues (16 somatic mutations, 9 polymorphisms, 8 variants). Somatic mutations/variants involved the following genes: TP53 (most common, 11/33, 33%), PTEN, BRAF, IDH1, NRAS, RET, APC, KDR, RB1, ERBB2, PTPN11. Most alterations were single nucleotide variants (n=31, 94%), the rest were indels (n=2, 6.5%). Of these 17 (51.51%) were detected in patient matched plasma samples (9 polymorphisms, 5 variants, 3 somatic mutations). All polymorphisms detected in tissues were detected in plasma. In conclusion, patients with glioblastoma have detectable cftDNA in the blood by NGS. Liquid biopsy in patients with glioblastoma could be used to phenotype tumors in unresectable patients, and to monitor disease progression and response to treatment.
IMST-01. COMBINING TOCA 511 AND 5-FLUOROCYTOSINE WITH CHECKPOINT INHIBITORS SIGNIFICANTLY REDUCED TUMOR BURDEN IN A MOUSE MODEL OF GLIOMA
Authors: Leah Mitchell, Kader Yagiz
Journal: Neuro-Oncology (2016)

Toca 511 (vocimagene amiretrorepvec), a retroviral replicating vector encoding an optimized yeast cytosine deaminase (CD) protein, selectively replicates and spreads in malignant cells. In infected cells, CD enzyme is expressed and converts 5-FC (5-fluorocytosine, an oral anti-fungal drug) to 5-FU, leading to both direct tumor cytotoxicity and extended immunotherapeutic effects. To date, over 130 patients with recurrent high grade glioma have been treated with Toca 511 & Toca FC. Treatment with Toca 511 & 5-FC showed several potential benefits, including extended overall survival compared to historical control, durable tumor responses and a favorable safety profile. The purpose of this study was to utilize a syngeneic mouse glioma model to determine if combinations of Toca 511 & 5-FC with checkpoint inhibitors are therapeutically useful. Tu-2449SC glioma cells (2% pretransduced with Toca 511) were implanted on the flanks of B6C3F1 mice and treatment initiated when tumors reached ~100mm3. 5-FC treated mice received 500 mg/kg/day IP (5 days per week). αPD-1 was administered at 300µg/mouse IP followed by 3 maintenance doses every 3 days of 200µg/mouse. αCTLA-4 (100µg/mouse, IP) was administered every 3 days (total of 6 treatments). Isotype antibodies were administered to control groups. The study was terminated after 3 cycles of 5-FC. Tumors and spleens were collected and immunophenotyped by flow cytometry. Tumor burden was significantly and markedly reduced with the addition of Toca 511 & 5-FC to either antibody treatment compared to antibody treatment groups. Treatment with Toca 511 & 5-FC alone was so highly effective at controlling tumor growth, that additive treatment with αPD-1, αCTLA-4 did not significantly reduce tumor burden further. Treatment with 5-FC significantly reduced tumor associated macrophages as well as myeloid derived suppressor cells and increased T cell populations. Follow-on combination studies with lower doses of Toca 511 and 5-FC are in progress.
Triggering of CD44 by Ultra-Low-Molecular-Weight Hyaluronan Induces Cell Death by Autophagy Via Endoplasmic Reticulum Stress in Acute Lymphoblastic Leukemia with MLL Gene Rearrangements
Authors: Shin Kasai, Yoshiyuki Furuichi, Norie Ando, Keiko Kagami, Kumiko Goi, Takeshi Inukai, Kanji Sugita
Journal: Blood (2012)
GENT-48. STRUCTURAL VARIANTS IN GLIOMAS AFFECT REGULATORY DNA ELEMENTS AND CAUSE ECTOPIC GENE EXPRESSION
Authors: Ming Tang, Zhengdao Lan, Samirkuma Amin, Floris Barthel, Ayush Raman, Siyuan Zheng, Qianghu Wang, Kunal Rai, Erik Sulman, Roel Verhaak
Journal: Neuro-Oncology (2016)

Although somatic single nucleotide variants in coding genes have been identified through large-scale genomic sequencing efforts such as TCGA, structural variants are less well understood, in part due to less mature methods for identification of this class of structural genomic variant. Structural variations are relatively large genomic alterations (> 100bp) including deletion, duplication, insertion, inversion, translocation and complex rearrangement. Although they are less common than point mutations, they may have great impact in regulating gene expression. We used a recently developed algorithm-Lumpy, which takes advantages of both split-reads pairs and discordant reads pairs, to identify genomic rearrangements in the whole genomes of 88 TCGA glioma samples. Among them, 14 samples are IDH mutants with 1p/19q co-deletion; 24 samples are IDH mutants without 1p/19q co-deletion; 44 samples are IDH wild type and 6 glioblastoma samples with unknown IDH status. In total, we identified 12,933 high-confidence structural variants. The frequency of structural variants significantly differed between glioma subtypes: IDH wild-type gliomas harbor the most structural variants followed by IDH mutants without 1p/19q co-deletion and IDH mutants with 1p/19q co-deletion. EGFR was identified as the most frequently affected gene by duplication. MTAP and MIR31HG were frequently co-deleted with CDKN2A. Of note, 40% of the breakpoints occur in the introns while more than 50% of the breakpoints occur in the distal intergenic regions, suggesting that SVs may disrupt distal regulatory DNA elements. To investigate the mechanisms of structural variants-dysregulated gene expression, we performed H3K27ac ChIP-seq in a subset of GBM tumors and glioma sphere-forming cells to identify glioma-specific enhancers compared with normal brain tissues. We found that VEGFA gene had a de-novo gained downstream enhancer. Integrating H3K27ac profiles with genomic rearrangements identified structural variants that rearranged super-enhancer of KIAA0195 to activate CNEP1R1 expression. Our study revealed new mechanisms of oncogene activation in gliomas.
DDIS-14. TARGETED LIPOSOMES WITH GADOLINIUM ARE MORE SENSITIVE AND MORE SPECIFIC FOR TUMOR DETECTION THAN MAGNEVIST
Authors: Xiaoli Liu, A.B. Madhankumar, Patti Miller, Becky Webb, Akiva Mintz, Qing Yang, James Connor
Journal: Neuro-Oncology (2016)

There is an unquestionable clinical need for MRI-contrast agents that are sensitive and specific in detection of GBM for image-guided treatment. The underlying mechanism for tumor detection with contrast enhanced MRI is that contrast agents extravagate into the brain areas due to breakdown of the BBB by the tumor. However, GBM aggressively infiltrates into brain tissues can frequently go undetected outside poorly defined tumor boarders by current MRI contrast agents, which is a major reason for relapses because it is difficult to resect completely. Furthermore, contrast-enhanced MRI cannot differentiate recurrent tumors from post-treatment inflammation and edema, which poses additional challenges to evaluate of effectiveness of radiation therapy. In this work, we address the critical need with a new approach for assessing brain tumor burden by using targeted liposomes encapsulating gadolinium. We use interleukin-13 (IL-13) as targeting agent because 75% of glioma cells overexpress IL-13Rα2 significantly. For this study, U87-luceferase cells were injected into the brain of athymic mice. The cancer growth was confirmed by IVIS (in vivo imaging system). Our results demonstrated the targeted liposomes were able to detect cancer cells earlier than Magnevist. Using dynamic imaging, the enhancement by our targeted liposomes took longer to clear, suggesting our liposomes delivered gadolinium intracellularly into the tumor cells, which could provide an effective ways to differentiate tumor growth from the enhanced tissues due to inflammation. Currently, we interrogate the relative efficacy of liposomes conjugated with wild type IL-13 to a variant of IL-13, known as Targeted Quadruple Mutant13 (TQM-13) that has been shown to be more selective for the IL-13Rα2 and binds with higher affinity than the wide type. In summary, targeted liposomes (IL-13-/TQM13-liposomes carrying gadolinium may significantly enhance the imaging technology than currently available to evaluate tumor burden.